<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-115563</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Study of a cohort of patients with Enterococcus spp. Bacteraemia. Risk factors associated to high-level resistance to aminoglycosides</dc:title>
<dc:description xml:lang="en">Objectives. To analyze a cohort of patients with Enterococcus sp. bacteraemia. Patients and methods. Retrospective and observational study of a cohort of non-pediatric in-patients with Enterococcus spp. bacteraemia (June 2007-September 2009). Data collection from clinical records was done according to a standard protocol. We analyzed epidemiological, clinical and microbiological data. Treatment with glycopeptides in non allergic patients or in case of betalactam susceptibility (ampicillin) was considered &#147;optimizable&#148;. Results. Three were 106 cases of bacteraemia (2.2/1000 admitted patients; 84% E. faecalis); 83% had an underlying condition; 88% nosocomial or health related cases. Urinary infection was present in 20% and primary bacteraemia in 47%. High level resistance to gentamicin (HLRG) was present in 60%; there was no vancomycin or linezolid resistance. Most frequent empiric treatments were penicillin-betalactamase inhibitor (25%) and glycopeptides (22%). Most frequent definitive treatment was glycopeptides (34%), being &#147;optimized&#148; 21% and 44% of empiric and definitive treatments, respectively. Mortality was 23% (related, 14%). In the multivariate analysis, risk factors associated with HLRG were nosocomial acquired infection (OR 6.083; 95CI% 1.428-25.915) and no-abdominal origin (OR 6.006; 95CI%1.398-25.805). In multivariate analysis, independent risk factors for mortality were: Pitt &gt; 3 (OR 14.405; 95CI%2.236-92.808) and active empiric treatment (OR 8.849; 95CI% 1.101-71.429).). Incidence in previous cohort was similar but HLRG rate has increased. Conclusions. Risk factors associated with HLRG were nosocomial acquired infection and no-abdominal origin. Risk factors for mortality were initial clinical severity and having received active empiric treatment. HLRG rate has increased (AU)</dc:description>
<dc:creator>García-Vázquez, Elisa</dc:creator>
<dc:creator>Yagüe, Genoveva</dc:creator>
<dc:creator>Ruiz, Joaquín</dc:creator>
<dc:creator>Gómez, Joaquín</dc:creator>
<dc:creator>Albendín, Helena</dc:creator>
<dc:creator>Hernández-Torres, Alicia</dc:creator>
<dc:creator>Canteras, Manuel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos. Analizar una cohorte de pacientes con bacteriemia enterocócica. Pacientes y métodos. Estudio retrospectivo-observacional de adultos ingresados con aislamiento de Enterococcus spp en hemocultivos (Junio 2007-Septiembre 2009). Se revisaron las historias clínicas siguiendo un protocolo que consideraba variables epidemiológicas, clínicas y microbiológicas. El tratamiento con glicopéptidos en pacientes no alérgicos o cepas sin resistencia a ampicilina se consideró &#147;optimizable&#148;. Resultados. Se detectaron 106 episodios (2/1000 pacientes ingresados; 84% E. faecalis); 83% presentaban comorbilidad de base; 88% de adquisición nosocomial/asociada a cuidados sanitarios. El foco fue urinario en 20% y desconocido en 47%; 60% tenían resistencia de alto nivel a gentamicina (RANG); no hubo cepas resistentes a vancomicina o linezolid. Los tratamientos empíricos más usados fueron penicilina-inhibidor de betalactamasas (25%) y glicopéptidos (22%). En el tratamiento definitivo el antibiótico más usado fue glicopéptido (34%), considerándose &#147;optimizado&#148; 21% de tratamientos empíricos y 44% de definitivos. La mortalidad global fue 23% (relacionada 14%). Se asociaron a RANG: adquisición nosocomial (OR 6,083; IC95% 1,428-25,915) y no tener foco abdominal (OR 6,006; IC95%1,398-25.805). Se asociaron a mayor mortalidad la gravedad clínica inicial (Pitt &gt; 3) (OR 14,405; IC95%2,236-92,808) y haber recibido un tratamiento empírico activo (OR 8,849; IC95% 1,101-71,429). La incidencia de la serie histórica fue similar y aumentó el porcentaje de RANG en la cohorte más reciente. Conclusiones. La adquisición nosocomial y el no tener foco abdominal se asociaron a RANG; la gravedad clínica inicial y recibir tratamiento empírico activo (que no optimizado) se asociaron a mayor mortalidad. Apreciamos un aumento en el porcentaje de RANG (AU)</dc:description>
<dc:source>Rev Esp Quimioter;26(3): 203-213, sept. 2013. tab</dc:source>
<dc:identifier>ibc-115563</dc:identifier>
<dc:title xml:lang="es">Estudio de una cohorte de pacientes con bacteriemias por Enterococcus spp. Factores de riesgo para resistencia de alto nivel a aminoglicósidos</dc:title>
<dc:subject>^d28621</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d22164^s22031</dc:subject>
<dc:subject>^d22164^s22021</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30421^s22001</dc:subject>
<dc:subject>^d30241^s22057</dc:subject>
<dc:subject>^d27512^s22001</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d23258^s22073</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d626</dc:subject>
<dc:subject>^d30241^s22016</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:type>article</dc:type>
<dc:date>201309</dc:date>
</metadata>
</record>
</ibecs-document>
